Cytokinetics’ (CYTK) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Cytokinetics (NASDAQ:CYTK) in a research report sent to investors on Monday,Benzinga reports. They currently have a $140.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on the company. Mizuho lifted their price target on Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, June 24th. Citizens Jmp boosted their price target on Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. JPMorgan Chase & Co. upped their price objective on Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Truist Financial increased their price objective on Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Wall Street Zen downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. Eighteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $103.37.

Cytokinetics Stock Performance

Shares of CYTK opened at $71.93 on Monday. Cytokinetics has a 52 week low of $47.22 and a 52 week high of $88.31. The firm has a market cap of $8.95 billion, a P/E ratio of -9.96 and a beta of 0.36. The firm’s 50-day simple moving average is $79.60 and its 200 day simple moving average is $72.41.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. During the same quarter last year, the business earned ($1.12) earnings per share. The company’s revenue was down 57.1% on a year-over-year basis. As a group, equities analysts forecast that Cytokinetics will post -6 earnings per share for the current year.

Insider Buying and Selling at Cytokinetics

In related news, Director B Lynne Parshall sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the sale, the director owned 10,784 shares of the company’s stock, valued at $770,840.32. This represents a 31.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 10,000 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $70.24, for a total value of $702,400.00. Following the transaction, the executive vice president owned 58,555 shares in the company, valued at approximately $4,112,903.20. This trade represents a 14.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 110,746 shares of company stock valued at $8,685,477 in the last three months. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

Large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC increased its position in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 673 shares during the period. Kemnay Advisory Services Inc. bought a new stake in Cytokinetics during the fourth quarter worth about $27,000. Kestra Advisory Services LLC bought a new stake in Cytokinetics during the fourth quarter worth about $29,000. Quarry LP acquired a new stake in Cytokinetics during the third quarter worth about $30,000. Finally, Advisory Services Network LLC acquired a new stake in Cytokinetics during the third quarter worth about $32,000.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New Phase 3 progress in non-obstructive hypertrophic cardiomyopathy (HCM) expands aficamten’s potential market beyond obstructive HCM. Additional study findings also suggest benefits across both forms of the disease, strengthening the outlook for Cytokinetics’ lead cardiovascular program. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM Can CYTK’s Aficamten Strengthen Its HCM Growth Prospects?
• Positive Sentiment: Evercore ISI and Goldman Sachs reaffirmed their Buy ratings on CYTK, while HC Wainwright also maintained its Buy recommendation. The repeated endorsements reinforce the favorable sell-side view of Cytokinetics’ pipeline and commercial potential. Evercore ISI Remains a Buy on Cytokinetics Goldman Sachs Reaffirms Its Buy Rating on Cytokinetics
• Neutral Sentiment: Management will participate in a Citi BioPharma investor conference on September 9. The event could provide pipeline or regulatory updates, but the announcement itself contained no new financial or clinical data. Cytokinetics to Participate in September Investor Conferences
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, and director B. Lynne Parshall sold 5,000 shares for about $357,400. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as signals of current management sentiment, but the sales may weigh modestly on investor confidence.
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a substantial full-year loss. Its latest quarterly revenue also declined year over year, leaving the stock dependent on clinical and regulatory execution rather than current earnings.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.